OTC ADVISORS, LLC: Huge Alert On – Trading Markets (press release)
www.otc-advisors.com names (OTCBB: NNAN | PowerRating) NaturalNano, Inc. , (OTCBB:OPCO) OurPet's Company , and (OTCBB: AEMD | PowerRating) Aethlon Medical, Inc. its "Bulls of the day"!
Visit: http://www.otc-advisors.com/disclaimer.htm for current profiles
Check out our forum at http://otc-advisors.com/forum.htm to get in on the chatter on who's hot and who's not.
To feature your publicly traded company in our alerts email us at info@otc-advisors.com.
To sign up for our free newsletter or to be added to our Quarterly Investment Magazine visit http://www.otc-advisors.com/contact.htm
Also, you can receive up to the minute stock alerts via our Twitter/Facbook page. www.twitter.com/otcadvisors or www.facebook.com/pages/OTC-ADVISORS-LLC/259891872296
Visit: www.otc-advisors.com
About NaturalNano, Inc.
NaturalNano, Inc. (OTCBB:NNAN) (Frankfurt:N3N) is a materials science company focused on developing and commercializing advanced nanocomposites. The Company is focused on additive technologies and processes, including its proprietary Pleximer that adds value to industrial polymers, plastics and composites. NaturalNano holds and/or licenses 20 patents and applications relating to Halloysite, as well as proprietary know-how for its extraction and separation processes, compositions, and derivatives. www.naturalnano.com
About the Naval Research Laboratory
Naval Research Laboratory is the corporate research laboratory for the Navy and Marine Corps and conducts a broad program of scientific research, technology and advanced development. NRL has served the Navy and the nation for over 80 years and continues to meet the complex technological challenges of today's world.
News Today :
ROCHESTER, N.Y., Feb 10, 2011 NaturalNano, Inc. (OTCBB:NNAN) (Frankfurt:N3N) (www.naturalnano.com), a provider of advanced nanomaterial and additive technology, announced it has signed an extension to its patent licensing agreement with the U.S. Naval Research Laboratory (NRL) covering the commercialization of products based on five (5) patents for extended release technologies.
NaturalNano's Acting CEO & President, James Wemett said, "The extension of this license agreement continues our relationship with the NRL. This relationship advances our strategic plan to commercialize products for a diverse range of markets and solidify our position as a leader in advanced nanomaterials." Wemett continued, "The continued opportunity to utilize and bring NRL's research technology to market and capitalize on the potential inherent in extended release applications is very important to NaturalNano."
Under the license agreement with NRL, NaturalNano has been granted rights to develop and commercialize five very important patents which will be utilized in the NNAN work in the cosmetics and fragrances fields. The continuation of the agreement bolsters NaturalNano's industry-leading intellectual property portfolio in nanomaterials, bringing the Company's total number of patents or pending applications, exclusively owned or licensed, to more than 20.
Visit: www.otc-advisors.com
About OurPet's Company
OurPet's designs, produces and markets a broad line of innovative, high-quality accessory and consumable products in the U.S. and overseas for improving the health, safety, comfort and enjoyment of pets. Investors and customers may visit www.ourpets.com for more information about the Company and its products. The Company's Websites include: www.smartscoop.com, www.ecopurenaturals.com, www.playnsqueak.com, and www.flappydogtoys.com and www.clipnosis.com .
News Today :
FAIRPORT HARBOR, OH, Feb 10, 2011 OurPet's Company (OTCBB: OPCO) (www.ourpets.com), a leading proprietary pet supply company today reported that all patent infringement accusations related to OurPet's Company's SmartScoop(R) Self Scooping Litter Box were been resolved on February 4, 2011. SmartScoop is a patented, automated self-cleaning cat litter box that offers a unique modular design for easy cleaning and maintenance using any type of clumping litter.
In 2007, Applica Consumer Products, the manufacturer of the LitterMaid(TM) Automatic Cat Litter Box, filed two lawsuits alleging that the SmartScoop infringed multiple claims of U.S. Patent No. RE 36,847 and U.S. Patent No. 6,082,302. As previously announced, in October 2010, in one of the lawsuits, the United States Court of Appeals for the Federal Circuit agreed with OurPet's legal position that the asserted patent claims were either not violated by the SmartScoop design and operation or were invalid. In the remaining patent infringement lawsuit, OurPet's is pleased to announce that the matter now has been resolved on satisfactory terms and will be dismissed shortly.
Dr. Steve Tsengas, PhD, President and CEO of OurPet's Company, commented "We are very pleased to reach a settlement agreement concerning SmartScoop following nearly four years of litigation. During that period we successfully defended and enhanced this product, increased our overall market presence, and significantly expanded our portfolio of innovative products for cats and dogs. It is gratifying that consumer needs for quality and innovation will be served through fair and open competition. We can now accelerate implementation of our growth strategy unencumbered by the prior litigation."
Annual expenditures in the United States for cat waste and odor control, excluding cat litter, are estimated to be approximately $130 million-$160 million. Automated litter boxes are a fast growing segment of this market, representing about 50% of those expenditures or approximately $65 million to $85 million in annual sales. Cats are increasingly popular as pets, especially for owners who work outside the home or travel frequently, due to the low level of maintenance required. The American Pet Products Association has estimated that approximately 37 million cats spend most of their time indoors. Waste and odor control are major challenges especially for indoor cats and SmartScoop provides an ideal solution. SmartScoop offers a great value for the consumer based on its competitive initial price and low operating costs.
Scott Fitzhugh, V.P. Sales & Marketing, stated "We are finalizing details for our SmartScoop re-launch, and the sales and marketing team is excited to deliver the automatic litter box solution cat owners desire. SmartScoop offers a high quality, reliable litter box that provides significant value throughout the life of the product. Today's settlement announcement coupled with significant improvements that have been made to the performance of SmartScoop will open the door to new opportunities for the company. OurPet's is focused on delivering the best experience possible in automatic litter boxes to the consumer and expanding the category revenue for all of our retail customers."
Visit: otc-advisors.com
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier(R) is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier(R) captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier(R) can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier(R) to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier(R) as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier(R) in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier(R) has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier(R) provides us with a pipeline into four significant market opportunities:
Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier(R) is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier(R) is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier(R) is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier(R) via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier(R) in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
News Today:
SAN DIEGO, Feb. 10, 2011 Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its President, Rod Kenley, was invited to present at the 4th Congress of the International Society for Hemodialysis (ISHD-2011) in India. The subject of his presentation is "The Treatment of HCV with Affinity Plasmapheresis." The conference will be held in New Delhi, India on March 3, 2011. Additional information can be accessed online at www.ishd2011.com.
(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
"It is particularly gratifying to be invited by the ISHD Congress to present since Delhi is where our human clinical trials are currently transpiring and this opportunity should provide good exposure of our technology to the medical community both in India and worldwide which may stimulate their consideration of referring patients for future treatment in India," stated Mr. Kenley.
About OTC-ADVISORS.COM
OTC-ADVISORS.COM is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTC-ADVISORS. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
For additional information: info@otc-advisors.com, www.otc-advisors.com, www.twitter.com/otcadvisors or www.facebook.com/pages/OTC-ADVISORS-LLC/259891872296
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
For full details on (AEMD) AEMD. (AEMD) has Short Term PowerRatings at TradingMarkets. Details on (AEMD) Short Term PowerRatings is available at This Link.
For full details on (NNAN) NNAN. (NNAN) has Short Term PowerRatings at TradingMarkets. Details on (NNAN) Short Term PowerRatings is available at This Link.
This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read our FAQ page at fivefilters.org/content-only/faq.php
Five Filters featured article: Collateral Damage - WikiLeaks In The Crosshairs.
